US FDA proposed rule may make generic drug makers liable for inadequate labeling
This article was originally published in SRA
Executive Summary
ln a move that could open the door to US lawsuits from patients claiming injuries from design defects in generic drugs, the Food and Drug Administration has signalled its plans to propose a rule that would allow generics makers to update their product labels with new safety information1.